Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 4/20 | 0.80 |
| ▸ | HPGD | P15428 | 3/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.80 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.80 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.80 |
| ▸ | FLT3 | P36888 | 1/20 | 0.69 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.67 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.67 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | DAO | P14920 | 1/20 | 0.54 |
| ▸ | CFD | P00746 | 1/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30920873 | 1.00 | SRD5A2 (0.80) | SRD5A2HPGDKDM4EHSD17B10ALDH1A1 | |
| SCHEMBL6087004 | 0.89 | FLT3 (0.66) | SRD5A2HPGDKDM4EHSD17B10ALDH1A1 | |
| SCHEMBL630515 | 0.89 | SRD5A2 (1.00) | SRD5A2HPGDKDM4EHSD17B10ALDH1A1 | |
| SCHEMBL8406972 | 0.87 | FLT3 (0.70) | SRD5A2HPGDKDM4EHSD17B10ALDH1A1 | |
| SCHEMBL3057182 | 0.85 | FLT3 (0.64) | SRD5A2HPGDKDM4EHSD17B10ALDH1A1 | |
| SCHEMBL10002831 | 0.84 | FLT3 (0.60) | SRD5A2HPGDKDM4EHSD17B10ALDH1A1 | |
| SCHEMBL4523117 | 0.84 | HPGD (0.68) | SRD5A2HPGDKDM4EHSD17B10ALDH1A1 | |
| SCHEMBL7174812 | 0.82 | SRD5A2 (0.88) | SRD5A2HPGDKDM4EHSD17B10ALDH1A1 | |
| SCHEMBL6542823 | 0.82 | NR1H4 (0.56) | SRD5A2HPGDKDM4EHSD17B10ALDH1A1 | |
| SCHEMBL4879379 | 0.81 | PDGFRB (0.59) | SRD5A2HPGDKDM4EHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103923765-A | Detergent Composition For Process Of Manufacturing Semiconductors And Displays | COWON INNOTECH INC | 2014-07-16 | — | — | CN | claimed |
| EP-2149552-A1 | 5,6 substituted benzamide derivatives as modulators of EP2 receptors | Bayer Schering Pharma AG (DE) | 2010-02-03 | — | — | EP | claimed |
| CN-1275942-C | Benzyloxy substituted indole compound and its analog and their production method and application | UNIV FUDAN (CN) | 2006-09-20 | — | — | CN | claimed |
| CN-1569834-A | Benzyloxy substituted indole compound and its analog and their production method and application | UNIV FUDAN (CN) | 2005-01-26 | — | — | CN | claimed |
| EP-4601635-A2 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | Maze Therapeutics, Inc. (US) | 2025-08-20 | — | — | EP | disclosed |
| US-20240199546-A1 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | HERCULES CAPITAL, INC., AS AGENT | 2024-06-20 | — | — | US | disclosed |
| WO-2024081748-A2 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| US-9869027-B2 | Cleaning composition and method of manufacturing metal wiring using the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2018-01-16 | — | — | US | disclosed |
| EP-2721011-B1 | PROSTAGLANDIN RECEPTOR EP2 ANTAGONISTS, DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO | UNIV EMORY (US) | 2017-09-06 | — | — | EP | disclosed |
| US-20160230289-A1 | CLEANING COMPOSITION AND METHOD OF MANUFACTURING METAL WIRING USING THE SAME | SAMSUNG DISPLAY CO LTD (KR) | 2016-08-11 | — | — | US | disclosed |
| US-9340759-B2 | Cleaning composition and method of manufacturing metal wiring using the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-05-17 | — | — | US | disclosed |
| US-20150136728-A1 | CLEANING COMPOSITION AND METHOD OF MANUFACTURING METAL WIRING USING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2015-05-21 | — | — | US | disclosed |
| US-6248772-B1 | HYPOTENSIVE AGENTS; ANTIARRHYTHMIA AGENTS; ANTIDIABETIC AGENTS; ANTIPROLIFERATIVE AGENTS | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 2001-06-19 | — | — | US | disclosed |
| US-6169107-B1 | USEFUL FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY INCREASED SODIUM/PROTON (NA.SUP.+ /H.SUP.+) EXCHANGER ACTIVITY, FOR EXAMPLE, HYPERTENSION, ARRHYTHMIA, ANGINA PECTORIS, CARDIAC HYPERTROPHY, DIABETES MELLITUS | SUMITOMO PHARMACEUTICAL CO., LTD. (JP) | 2001-01-02 | — | — | US | disclosed |
| US-5866589-A | Alkyl substituted piperadinyl and piperazinyl anti-AIDS compounds | PHARMACIA & UPJOHN COMPANY (US) | 1999-02-02 | — | — | US | disclosed |
| EP-0622356-B1 | Indoloylguanidine derivatives as inhibitors of sodium-hydrogen exchange | SUMITOMO PHARMA (JP) | 1998-07-01 | — | — | EP | disclosed |
| EP-0797576-A1 | ALKYL SUBSTITUTED PIPERADINYL AND PIPERAZINYL ANTI-AIDS COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 1997-10-01 | — | — | EP | disclosed |
| WO-1996018628-A1 | ALKYL SUBSTITUTED PIPERADINYL AND PIPERAZINYL ANTI-AIDS COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 1996-06-20 | — | — | WO | disclosed |
| EP-0708091-A2 | Indoloylguanidine derivatives | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1996-04-24 | — | — | EP | disclosed |
| EP-0622356-A1 | Indoloylguanidine derivatives as inhibitors of sodium-hydrogen exchange | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1994-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199546-A1 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | SLC6A19, SLC2A9, SLC6A3 | SRD5A2 975/4885HPGD 2264/4885KDM4E 3995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.